Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Colorcon
Medtronic
McKesson
Chinese Patent Office
Healthtrust
Covington
Farmers Insurance
Daiichi Sankyo
Accenture

Generated: August 20, 2017

DrugPatentWatch Database Preview

SANOFI AVENTIS US Company Profile

« Back to Dashboard

What is the competitive landscape for SANOFI AVENTIS US, and when can generic versions of SANOFI AVENTIS US drugs launch?

SANOFI AVENTIS US has one hundred and thirty-six approved drugs.

There are fifty-six US patents protecting SANOFI AVENTIS US drugs.

There are one thousand and thirty-one patent family members on SANOFI AVENTIS US drugs in seventy-three countries.

Summary for Applicant: SANOFI AVENTIS US

Patents:56
Tradenames:113
Ingredients:93
NDAs:136
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us
JEVTANA KIT
cabazitaxel
SOLUTION;IV (INFUSION)201023-001Jun 17, 2010RXYesYes► Subscribe► Subscribe► Subscribe
Sanofi Aventis Us
APIDRA SOLOSTAR
insulin glulisine recombinant
INJECTABLE;SUBCUTANEOUS021629-003Feb 24, 2009RXYesNo► Subscribe► SubscribeY ► Subscribe
Sanofi Aventis Us
METATENSIN #2
reserpine; trichlormethiazide
TABLET;ORAL012972-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Sanofi Aventis Us
LOVENOX (PRESERVATIVE FREE)
enoxaparin sodium
INJECTABLE;SUBCUTANEOUS020164-008Jun 2, 2000APRXYesNo► Subscribe► Subscribe► Subscribe
Sanofi Aventis Us
APIDRA SOLOSTAR
insulin glulisine recombinant
INJECTABLE;SUBCUTANEOUS021629-003Feb 24, 2009RXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Sanofi Aventis Us

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us
KERLEDEX
betaxolol hydrochloride; chlorthalidone
TABLET;ORAL019807-001Oct 30, 1992► Subscribe► Subscribe
Sanofi Aventis Us
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION
fexofenadine hydrochloride; pseudoephedrine hydrochloride
TABLET, EXTENDED RELEASE;ORAL021704-002Jan 24, 2011► Subscribe► Subscribe
Sanofi Aventis Us
ALLEGRA ALLERGY
fexofenadine hydrochloride
TABLET;ORAL020872-010Jan 24, 2011► Subscribe► Subscribe
Sanofi Aventis Us
LOZOL
indapamide
TABLET;ORAL018538-001Jul 6, 1983► Subscribe► Subscribe
Sanofi Aventis Us
AMBIEN
zolpidem tartrate
TABLET;ORAL019908-002Dec 16, 1992► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for SANOFI AVENTIS US drugs

Drugname Dosage Strength Tradename Submissiondate
nicotine
Transdermal System7 mg/24 hrs, 14 mg/24 hrs, and 21 mg/24 hrs
NICODERM CQ
5/30/2014
dronedarone hydrochloride
Tablets400 mg
MULTAQ
7/1/2013
oxaliplatin
Injection5 mg/mL, 40 mL vial
ELOXATIN
3/23/2011
fexofenadine hydrochloride
Oral Suspension30 mg/5 mL
ALLEGRA
1/25/2010
docetaxel
Injection40 mg/mL, 0.5 mL and 2 mL vials
TAXOTERE
6/30/2009
clopidogrel bisulfate
Tablets300 mg
PLAVIX
3/4/2009
oxaliplatin
Injection200 mg/40 mL
ELOXATIN
7/16/2007
oxaliplatin
Injection5 mg/mL, 10 mL and 20 mL vials
ELOXATIN
2/9/2007
oxaliplatin
For Injection50 mg/vial and 100 mg/vial
ELOXATIN
2/9/2007
enoxaparin sodium
Injection100 mg/mL, 3 mL vials
LOVENOX
12/7/2006
irbesartan and hydrochlorothiazide
Tablets300 mg/25 mg
AVALIDE
6/6/2006
zolpidem tartrate
Extended-release Tablets6.25 mg
AMBIEN CR
2/24/2006
zolpidem tartrate
Extended-release Tablets12.5 mg
AMBIEN CR
1/19/2006
irbesartan and hydrochlorothiazide
Tablets150 mg/12.5 mg and 300 mg/12.5 mg
AVALIDE
11/10/2004
irbesartan
Tablets75 mg, 150 mg and 300 mg
AVAPRO
5/25/2004

Premature patent expirations for SANOFI AVENTIS US

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
► Subscribe ► Subscribe

Non-Orange Book Patents for Sanofi Aventis Us

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,553,299Drive mechanisms suitable for use in drug delivery devices► Subscribe
6,232,477 Methods of preparing new taxoids and pharmaceutical compositions containing them► Subscribe
8,574,198Drive mechanisms suitable for use in drug delivery devices► Subscribe
8,876,782Drive mechanisms suitable for use in drug delivery devices► Subscribe
6,046,322 Process for the production of fludarabine-phosphate lithium, sodium, potassium, calcium and magnesium salts and purification process for the production of fludarabine-phosphate and fludarabine-phosphate with a purity of at least 99.5%► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Sanofi Aventis Us Drugs

Country Document Number Estimated Expiration
Bulgaria100951► Subscribe
Mexico336339► Subscribe
World Intellectual Property Organization (WIPO)2004078242► Subscribe
BrazilPI0408112► Subscribe
Hong Kong1037319► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Sanofi Aventis Us Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2002 00001Denmark► SubscribeDKCTFF , , EXPIRES:
C/GB99/008United Kingdom► SubscribePRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
C0036Belgium► SubscribePRODUCT NAME: CLOPIDOGREL HYDROGENE SULFATE; REGISTRATION NO/DATE IN FRANCE: EU/1/98 /069/001 DU 19980715; REGISTRATION NO/DATE AT EEC: DU EU/1-/98/069/001
C0009Belgium► SubscribePRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
00160Netherlands► SubscribePRODUCT NAME: INSULINE DETEMIRUM; NAT. REGISTRATION NO/DATE: EU/1/04/278/001EU/1/04/278/002EU/1/04/278/003EU/1/04/278/005EU/1/04/278/004EU/1/04/278/006EU/1/04/278/007EU/1/04/278/008EU/1/04/278/009 2004010601; FIRST REGISTRATION: 563705637156372EU/1/04/278/001 T/M -/009 2003101110
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
AstraZeneca
Boehringer Ingelheim
Medtronic
Moodys
Teva
Argus Health
McKesson
Queensland Health
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot